close

Enter

Log in using OpenID

Dementia Drugs Market Top Players Success Milestones And Forecasts To 2026

embed
The global dementia drugs market estimated to be valued at US$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018–2026).
Dementia Drugs Market Size, Outlook,
Future Analysis And Synthesis By 2026
Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various
behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can
gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently,
there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in
pipeline, which are expected to be launched in the near future, in turn propelling growth of the
dementia drugs market.
Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1664
Market Dynamics
Increasing aging population along with its associated complications is the major driving factor for growth
of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention
(CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14
million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47
million people suffer from dementia and around 10 million new cases are reported annually. Increasing
incidence of dementia coupled with growing demand for therapy is expected to favor growth of the
dementia drugs market in the near future. According to Australian Institute of Health and Welfare
(AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020,
and around 900,000 by 2050.
Increasing number of pipeline products is expected to drive growth of the dementia drugs
market
Major factors fueling growth of the dementia drugs market include the large number of drugs in the
pipeline, which are expected to enter into the market by 2020-2022. According to the study published
by Translational Research and Clinical Intervention, in September 2017, it is recorded that 105 new
drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These
new products use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid
precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor
antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint
efforts is also boosting growth of the market. For instance, in November 2017, Novartis and Amgen,
along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1
inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease.
Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT to boost
demand in emerging economies
On the basis of geography, the global dementia drugs market can be segmented into six major
regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North
America is expected to hold the largest market, owing to major approval of drugs in this region
and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in
the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases,
especially in China, India.
Report includes chapters which deeply display the following deliverable about industry :
• Dementia Drugs Market Research Objective and Assumption
• Dementia Drugs Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Dementia Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Dementia Drugs Market, By Regions
• Dementia Drugs Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Dementia Drugs Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Dementia Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Dementia Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Some of the top companies operating in the dementia drugs market are Eisai, Inc., Janssen
Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis
AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical
International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Detailed Segmentation:
•Global Dementia Drugs Market, By Drug Class:
•MAO Inhibitors
•Cholinesterase Inhibitors
•Glutamate Inhibitors
•Global Dementia Drugs Market, By Distribution Channel:
•Hospital Pharmacies
•Retail Pharmacies
•Others
•Global Dementia Drugs Market, By Region:
•North America
•Europe
•Asia Pacific
•Latin America
•Middle East
•Africa
For More Information, Browse at https://www.coherentmarketinsights.com/marketinsight/dementia-drugs-market-1664
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials
for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
https://www.coherentmarketinsights.com/phase-xs/
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials
for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master77   documents Email
Document
Category
Health and Medicine
Views
3
File Size
348 KB
Tags
drugs, Dementia Drugs Market
1/--pages
Report inappropriate content